Q. How has immunotherapy influenced surgical oncology?
Doctor Answer is medically reviewed by SecondMedic medical review team.
Immunotherapy has had a major impact on the field of surgical oncology in recent years, revolutionizing how we approach cancer treatment and improving patient outcomes. To provide some context, consider that traditional radiation and chemotherapy treatments for cancer are limited by the need to target specific cancer types, requiring the doctor to evaluate a variety of general treatments before singling out one for their patient. Additionally, these treatments can have severe side-effects due to their broad scope approach.
Immunotherapy offers an alternative way of treating cancer as it works by harnessing the body’s own immune system; stimulating it to recognize mutated cells and destroy them while also reinforcing healthy tissue with minimal side effects. As this therapy is tailored to individual patients based upon their particular genetics and biochemistry it has been able to create more targeted approaches than chemo or radiation alone. This improved targeting helps achieve better clinical results while reducing toxicity when compared traditional methods such as chemotherapy or radiation therapy therapies providing an immense value within surgical oncology in terms of non-invasive options over surgery.
From advancements in personalized medicine, such as CAR T-cell immune therapy which targets leukemia cells specifically (by engineering patients own T-cells) through intranasal delivery systems that take advantage of our natural ability to sense foreign substances (such as anti-cancer agents), immunotherapies offer a cutting edge platform for drug delivery that may enable precision medicine approaches against many diseases including various cancers which present great promise but remain difficult challenges today.
The use of immunotherapies brings many benefits compared with existing treatment modalities used in surgical oncology; such as fewer adverse events due reduced systemic exposure from drugs; improved control over localized disease progression through greater selectivity and efficacy at lower doses; reduction cost associated with decreased hospital stays associated with surgeries; potential elimination of recurrence risk since local or regional tumor sites targeted by therapeutics may be completely destroyed during course treatment—allowing less intensive post operative follow up efforts if needed—and increased safety associated with targeting small volumes allowing higher dose delivery while minimizing systemic exposure affect individuals suffering from cancer among other diseases.
Related Posts
Aptamil Pepti Infant Formula 0 to 12 Months Tin 400gm
Brand: Nutricia International Private Limited
₹2000.00₹1960.00
View Details
Neocate LCP Infant Formula Powder 400GM
Brand: Nutricia International Private Limited
